← Leaderboards
Ajay S Yekkirala
Blue Therapeutics, Inc.
$4,957,731
Attributed
$4,957,731
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2016–20$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$4,957,731 · 2
By mechanism
R44$4,653,046 · 1
R43$304,685 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculePainOxycodoneSmall Business Innovation Research GrantFrequenciesDoseEffective TherapyOpioid ReceptorPhysical DependenceRodentLigandsUnited StatesHydrocodonePrescription OpioidAnalgesicsCoupledMorphineOpioidDrug Seeking BehaviorFutureAgonistFormulationClinical TrialsLead
Grant awards (6)
Completion of IND-package for a novel, non-narcotic painkiller$1,776,585
R44 · FY2020 · DA · contact PI
Completion of IND-package for a novel, non-narcotic painkiller$1,474,091
R44 · FY2019 · DA · contact PI
Blue Therapeutics I-Corps Application$55,000
R43 · FY2019 · DA · contact PI
Identification of lead chemical scaffolds targeting opioid receptor heteromers.$249,685
R43 · FY2018 · DA · contact PI
Development of a non-addictive analgesic targeting opioid receptor heteromers.$655,681
R44 · FY2017 · DA · contact PI
Development of a non-addictive analgesic targeting opioid receptor heteromers.$746,689
R44 · FY2016 · DA · contact PI